Michael Herold

Summary

Affiliation: HELIOS Klinikum Wuppertal
Country: Germany

Publications

  1. ncbi request reprint Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
    M Herold
    HELIOS Klinikum Erfurt GmbH, 2 Medizinische Klinik, Bereich Hamatologie Onkologie, Nordhäuserstr 74, 99089, Erfurt, Germany
    J Cancer Res Clin Oncol 132:105-12. 2006
  2. ncbi request reprint Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study
    Michael Herold
    HELIOS Klinikum Erfurt GmbH, 2 Medizinische Klinik, Bereich Hamatologie Onkologie, Erfurt, Germany
    J Clin Oncol 25:1986-92. 2007
  3. ncbi request reprint Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab
    M Herold
    HELIOS Klinikum Erfurt, 2 Medizinische Klinik, Department of Hematology Oncology, Nordhäuserstrasse 74, Germany
    Ann Hematol 82:77-9. 2003
  4. ncbi request reprint Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment
    Michael Herold
    HELIOS Klinikum Erfurt, Erfut, Germany
    Value Health 6:167-74. 2003
  5. ncbi request reprint The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use
    Michael Herold
    HELIOS Klinikum Erfurt II Medizinische Klinik, Abt Hämatologie Onkologie, Erfurt, Germany
    Haematologica 87:719-29; discussion 729. 2002
  6. ncbi request reprint Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab
    M Herold
    2 Medizinische Klinik, Klinikum Erfurt GmbH, Germany
    Ann Hematol 79:332-5. 2000
  7. ncbi request reprint Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
    Holger Schulz
    Cochrane Haematological Malignancies Group, Clinic I of Internal Medicine I, University of Cologne, Kerpenerstrasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 99:706-14. 2007
  8. doi request reprint Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients
    Carsten Hirt
    Hämatologie und Onkologie Transplantationszentrum, Universitätsklinikum Greifswald, Greifswald, Germany
    Br J Haematol 141:631-40. 2008
  9. ncbi request reprint Rituximab therapy for indolent non-Hodgkin's lymphoma
    Anton Hagenbeek
    University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands
    Anticancer Drugs 13:S11-7. 2002
  10. ncbi request reprint Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
    Holger Schulz
    Clinic I of Internal Medicine, University of Cologne, Cologne 50924, Germany
    Blood 100:3115-20. 2002

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
    M Herold
    HELIOS Klinikum Erfurt GmbH, 2 Medizinische Klinik, Bereich Hamatologie Onkologie, Nordhäuserstr 74, 99089, Erfurt, Germany
    J Cancer Res Clin Oncol 132:105-12. 2006
    ....
  2. ncbi request reprint Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study
    Michael Herold
    HELIOS Klinikum Erfurt GmbH, 2 Medizinische Klinik, Bereich Hamatologie Onkologie, Erfurt, Germany
    J Clin Oncol 25:1986-92. 2007
    ..We conducted a randomized trial comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus rituximab with MCP alone...
  3. ncbi request reprint Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab
    M Herold
    HELIOS Klinikum Erfurt, 2 Medizinische Klinik, Department of Hematology Oncology, Nordhäuserstrasse 74, Germany
    Ann Hematol 82:77-9. 2003
  4. ncbi request reprint Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment
    Michael Herold
    HELIOS Klinikum Erfurt, Erfut, Germany
    Value Health 6:167-74. 2003
    ..The purpose of this analysis was to assess the real-life direct costs of drug delivery for frequently used chemotherapeutic regimens in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL)...
  5. ncbi request reprint The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use
    Michael Herold
    HELIOS Klinikum Erfurt II Medizinische Klinik, Abt Hämatologie Onkologie, Erfurt, Germany
    Haematologica 87:719-29; discussion 729. 2002
    ..This international analysis (Canada, Germany, Italy) was established to estimate the overall direct cost of treating patients with relapsed indolent NHL and determine the main cost components of treatment...
  6. ncbi request reprint Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab
    M Herold
    2 Medizinische Klinik, Klinikum Erfurt GmbH, Germany
    Ann Hematol 79:332-5. 2000
    ..One patient was re-treated successfully three times after relapses. Both patients were premedicated with prednisone (100 mg) 30 min prior to the infusion to prevent cytokine release and the antibody infusions were well tolerated...
  7. ncbi request reprint Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
    Holger Schulz
    Cochrane Haematological Malignancies Group, Clinic I of Internal Medicine I, University of Cologne, Kerpenerstrasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 99:706-14. 2007
    ....
  8. doi request reprint Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients
    Carsten Hirt
    Hämatologie und Onkologie Transplantationszentrum, Universitätsklinikum Greifswald, Greifswald, Germany
    Br J Haematol 141:631-40. 2008
    ..This study demonstrated that R-MCP led to a rapid and sustained eradication of CLC and a > or = 2 log CLC reduction was associated with a superior quality and duration of the clinical response...
  9. ncbi request reprint Rituximab therapy for indolent non-Hodgkin's lymphoma
    Anton Hagenbeek
    University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands
    Anticancer Drugs 13:S11-7. 2002
    ..Rituximab is therefore an excellent treatment option both as first-line and as salvage therapy for patients with indolent NHL...
  10. ncbi request reprint Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
    Holger Schulz
    Clinic I of Internal Medicine, University of Cologne, Cologne 50924, Germany
    Blood 100:3115-20. 2002
    ..The median duration of response was 75 weeks. We conclude that the combination of rituximab and fludarabine is feasible and effective in patients with B-CLL...
  11. ncbi request reprint Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
    Manuela A Bergmann
    Medical Clinic III, University Hospital Grosshadern, Ludwig Maximilians University Munich
    Haematologica 90:1357-64. 2005
    ..To determine the maximal tolerated dose, dose-limiting toxicity and the optimal therapeutic dose of bendamustine for further phase III clinical trials the GCLLSG designed a phase I/II study for pre-treated CLL patients...
  12. ncbi request reprint Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study
    Luisa Mantovani
    Department of Internal Medicine I, St Georg s Hospital, Leipzig, Germany
    Leuk Lymphoma 43:265-74. 2002
    ..The data suggest that a randomized trial should now be undertaken to examine whether mir-IDAC has clinical advantages over HIDAC...
  13. ncbi request reprint Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy
    Stefanie Srock
    Department of Hematology and Oncology, Charite Campus Virchow Klinikum, Berlin, Germany
    Leuk Lymphoma 48:905-11. 2007
    ..5 years so far. Long-term toxicity, as determined based on hematological and immunological parameters, was mild...
  14. ncbi request reprint Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO)
    Michael Koenigsmann
    Hematology Oncology Departments, University Magdeburg, Germany
    Leuk Lymphoma 45:1821-7. 2004
    ..Dose level 1 with 30 mg/m2/d of both drugs on days 1 to 3 was defined as the recommended dose. Despite unfavorable prognostic features (histologic subtype, stage of disease, pretreatment) response rates were good with this regimen...